Disease progression in rheumatoid arthritis

"Disease progression in rheumatoid arthritis" is not a specific molecule, receptor, enzyme, or other canonical therapeutic target, but rather describes the clinical worsening over time seen in patients with rheumatoid arthritis. Disease progression refers to the cumulative pathological changes—such as persistent synovial inflammation leading to joint damage and systemic manifestations—that occur if the underlying autoimmune process remains uncontrolled[1][3][7]. \n\nThe molecular drivers of disease progression in RA include multiple cell types and mediators, such as T cells, B cells, macrophages, synovial fibroblasts, neutrophils, mast cells; pro-inflammatory cytokines like TNF-alpha and IL-6; matrix metalloproteinases that degrade cartilage; autoantibodies such as rheumatoid factor and anti-citrullinated protein antibodies[1][3][5]. These are true therapeutic targets. Drugs that slow or halt disease progression act by targeting these molecules or pathways—for example:\n - TNF inhibitors block tumor necrosis factor-alpha.\n - IL-6 inhibitors block interleukin 6 signaling.\n - JAK inhibitors interfere with Janus kinase-mediated cytokine signaling.\n\nThus,\n> "Disease progression in rheumatoid arthritis" is not itself a druggable molecular target, but an outcome resulting from complex interactions among many immune system components. For structured data purposes it should be flagged as incorrect when listed as a single molecular/receptor target.\n\nIf you need information on actual targets involved in RA pathogenesis—such as "Tumor necrosis factor," "Interleukin 6 receptor," "Janus kinase 1," etc.—please specify which one(s) you want detailed information about[1][3][5].

Other names

RA disease progressionRheumatoid arthritis progressionProgression of rheumatoid arthritis